Onconic Therapeutics Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-34
RECRUITING2
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| JPI-547 NCT07364422 |
P1/2 | Not yet recruiting | Gastric Cancer (GC) | 49 | 2026-02-28 |
| NCT07160790 NCT07160790 |
P3 | Not yet recruiting | Non-erosive Gastroesophageal Reflux Disease | 321 | 2026-06-30 |
| JP-1366 10 mg NCT06439563 |
P3 | Recruiting | Peptic Ulcer | 364 | 2027-08 |
| NCT07875933 NCT07875933 |
P3 | Not yet recruiting | H. Pylori Eradication Therapy | 414 | 2028-09-06 |
| JP-1366 10 mg NCT07732075 |
P3 | Not yet recruiting | Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD) | 384 | 2028-10-30 |
| JPI-547 NCT07370818 |
P2 | Not yet recruiting | Ovarian Cancer | 81 | 2029-12-31 |
| JPI-547 NCT05257993 |
P1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma | 71 | 2030-04 (+80 mo) |